<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459575</url>
  </required_header>
  <id_info>
    <org_study_id>ATV 2005</org_study_id>
    <nct_id>NCT01459575</nct_id>
  </id_info>
  <brief_title>Unboosted Atazanavir as Initial ART Therapy in China</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BMS company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for AIDS/STD Control and Prevention, China CDC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Pilot study.The study hypothesis is that the feasibility and efficacy
      of a non-boosted ATV based HAART will be well as the first line treatment in a Chinese
      resource-limited setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Antiretroviral Therapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ART-naïve patients, established HIV infection &gt; 6 months with CD4 count of 100~350 cell/mm3
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  The subject should have established HIV infection more than 6 month.

          -  Qualifying plasma HIV RNA ≥ 2,000 c/mL and a CD4 cell count within 100 - 350 cells/mm3

          -  ≥16 years of age

          -  Both females of child-bearing potential and males must utilize effective barrier
             contraception - other contraception in addition to barrier methods are permitted

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the
             study in such a manner that the risk of pregnancy is minimized.

        Exclusion Criteria:

          -  Patients who are unwilling or unable to use an acceptable method to avoid pregnancy
             for the entire study period and for up to 4 weeks after the study.

          -  Presence of a newly diagnosed HIV-related opportunistic infection or any medical
             condition requiring acute therapy at the time of enrollment.

          -  History of hemophilia

          -  Proven or suspected acute hepatitis in the 30 days prior to study entry. Subjects with
             chronic hepatitis are eligible provided that their liver function enzymes are &lt; 3
             times the upper limit of normal.

          -  Presence of cardiomyopathy.

          -  A history of arrhythmia or clinical symptoms potentially related to heart block or
             second / third degree heart block.

          -  Inability to tolerate oral medication

          -  Presence of a newly diagnosed HIV-related opportunistic infection or any medical
             condition requiring acute therapy at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fujie Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for AIDS/STD control and prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yan Zhao</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Center for AIDS/STD Control and Prevention, China CDC</investigator_affiliation>
    <investigator_full_name>NCAIDS</investigator_full_name>
    <investigator_title>National Center for AIDS/STD Control and Prevention</investigator_title>
  </responsible_party>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>China</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

